Join
Live feed
·
PRReleasevia Quantisnow
Artelo Biosciences Inc. logo

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

ByQuantisnow·Wall Street's wire, on your screen.
ARTL· Artelo Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARTL (Artelo Biosciences Inc.) and more on Quantisnow.